Identifying a survival-associated cell type based on multi-level transcriptome analysis in idiopathic pulmonary
Fei Xu1, Yun Tong1, Wenjun Yang1
1Department of Pharmacogenomics, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Respiratory Research
|March 16, 2024
Summary
Researchers identified a novel alveolar type 2 cell subtype (ATII-CCL20) in idiopathic pulmonary fibrosis (IPF) patients. Higher proportions of these cells correlate with worse IPF prognosis and increased immune cell infiltration and metabolic dysfunction.
Area of Science:
- Pulmonary Medicine
- Cell Biology
- Genomics
Background:
- Idiopathic pulmonary fibrosis (IPF) is a severe lung disease with poor prognosis.
- Significant variability exists in IPF patient survival, with unclear underlying mechanisms.
Purpose of the Study:
- To identify novel cellular subtypes and molecular mechanisms contributing to IPF progression.
- To develop improved risk stratification tools for IPF patients.
Main Methods:
- Integration of single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing data from IPF patients.
- Unsupervised clustering and deconvolution algorithms to analyze cell populations.
- Construction of decision trees and nomograms for risk assessment.
Main Results:
- Discovery of a distinct alveolar type 2 cell subtype expressing high levels of CCL20 (ATII-CCL20).
- A higher proportion of ATII-CCL20 cells is associated with worse prognosis in IPF patients.
- Increased immune cell infiltration and altered metabolic functions were observed in IPF patients with higher ATII-CCL20 proportions.
Conclusions:
- The ATII-CCL20 cell subtype is a novel risk factor for poor prognosis in IPF.
- This cell subtype is linked to key pathological processes including immune infiltration and metabolic dysregulation.
- The findings provide a basis for enhanced risk stratification and potential therapeutic targets in IPF.
